Gotham Asset Management’s Abiomed Inc ABMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-3,632
Closed -$892K 1343
2022
Q3
$892K Sell
3,632
-4,348
-54% -$1.17M 0.03% 689
2022
Q2
$1.98M Buy
+7,980
New +$2.15M 0.06% 376
2021
Q4
Sell
-677
Closed -$220K 1263
2021
Q3
$220K Buy
+677
New +$229K 0.01% 947
2021
Q2
Sell
-1,029
Closed -$328K 1144
2021
Q1
$328K Buy
+1,029
New +$329K 0.01% 810
2020
Q1
Sell
-40,371
Closed -$6.89M 1248
2019
Q4
$6.89M Buy
40,371
+37,586
+1,350% +$6.97M 0.13% 229
2019
Q3
$495K Sell
2,785
-1,482
-35% -$320K 0.01% 777
2019
Q2
$1.11M Buy
4,267
+1,617
+61% +$429K 0.02% 610
2019
Q1
$757K Buy
+2,650
New +$881K 0.01% 734
2018
Q1
Sell
-5,297
Closed -$993K 1108
2017
Q4
$993K Buy
+5,297
New +$989K 0.01% 591
2016
Q3
Sell
-3,013
Closed -$329K 1081
2016
Q2
$329K Buy
+3,013
New +$300K ﹤0.01% 796
2015
Q4
Sell
-15,078
Closed -$1.4M 1040
2015
Q3
$1.4M Sell
15,078
-52,351
-78% -$4.61M 0.01% 577
2015
Q2
$4.43M Buy
67,429
+45,000
+201% +$2.99M 0.04% 469
2015
Q1
$1.6M Sell
22,429
-11
-0% -$597 0.01% 544
2014
Q4
$854K Buy
+22,440
New +$708K 0.01% 651
2014
Q2
Sell
-25,692
Closed -$669K 1123
2014
Q1
$669K Buy
+25,692
New +$711K 0.01% 739

Other funds holding ABMD

Gotham Asset Management's ABMD Position: Q4 2022 in Review

Gotham Asset Management sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 3,632 shares — an estimated $892K sold.

Gotham Asset Management first reported a position in ABMD in Q1 2014 and held it in 15 quarters. The position peaked at $6.89M in Q4 2019. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Gotham Asset Management reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Gotham Asset Management sold 3,632 Abiomed Inc shares in Q4 2022, an estimated $892K.
  • Gotham Asset Management first reported a position in Abiomed Inc in Q1 2014 and held it in 15 quarters.
  • Gotham Asset Management's Abiomed Inc position peaked at $6.89M in Q4 2019.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Gotham Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.